This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.
Global biotherapeutics leader, CSL Behring today announced that the Australian Therapeutic Goods Administration (TGA) has approved AFSTYLA® [lonoctocog alfa].
CSL Behring marks World Hemophilia Day by donating its bleeding disorders medicines to the World Federation of Hemophilia (WFH).
Global biotherapeutics leader CSL Behring announced today that the European Commission has granted marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for children and adults with haemophilia A.
Health Canada has approved AFSTYLA [Antihemophilic Factor VIII (Recombinant), SingleChain], CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.
Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for the treatment of hemophilia B.